TW Newsdesk, March 14: Pfizer is set to spend $43 billion to buy Seagen and deepen its reach into treating cancer. The pharmaceutical giant stated that it will pay $229 per Seagen share.

“Together, Pfizer and Seagen seek to accelerate the next generation of cancer breakthroughs and bring new solutions to patients by combining the power of Seagen’s antibody-drug conjugate (ADC) technology with the scale and strength of Pfizer’s capabilities and expertise,” Pfizer Chairman and Chief Executive Officer Dr Albert Bourla mentioned.